Cat.No. : CSC-RO0130 Host Cell: Ba/F3
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0130 |
| Description | Ba/F3-EGFR-DEL19/C797S cell line is a stably transfected cell line which expresses human epidermal growth factor receptor (EGFR) with DEL19 and C797S mutations. |
| Target Gene | EGFR |
| Gene Species | Homo sapiens (Human) |
| Host Cell | Ba/F3 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Growth Conditions | 37 °C, 5% CO2 |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Biosafety Level | 2 |
| Thawing & Subculturing Instructions | 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL. |
| Growth Properties | Suspension, round |
| Freeze Medium | Frozen with 70% medium, 20% FBS, 10% DMSO |
| Freezing Instructions | Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Researchers investigated the efficacy of WX-0593, a potent ALK inhibitor, in combination with an EGFR monoclonal antibody (QL1203 or Vectibix), for treating xenograft tumors harboring mutant EGFR and osimertinib-resistant mutations (EGFR/T790M/C797S). In vitro studies on four EGFR triple-mutant cell lines and in vivo experiments on xenograft tumor models in BALB/c nude mice derived from H1975 and Ba/F3 cell lines were conducted. WX-0593 and Vectibix exhibited synergistic inhibition on the proliferation of EGFR triple-mutant Ba/F3 cell lines. In vivo, WX-0593 showed therapeutic efficacy when combined with QL1203 or Vectibix, with modest antitumor effects observed at 25 mg/kg and enhanced effects at 75 mg/kg. No significant side effects were observed, and pharmacokinetic analysis revealed increased serum levels and prolonged duration of QL1203 or Vectibix when combined with WX-0593. This combination therapy demonstrates promising antitumor efficacy and safety, offering a potential treatment strategy for osimertinib-resistant EGFR triple-mutant NSCLC patients.
Figure 1. The synergistic effect of WX-0593 in combination with Vectibix on the proliferation of EGFR triple-mutant cell lines was investigated by researchers. Significant inhibition of cell proliferation was observed in Ba/F3 (EGFR L858R/T790M/C797S) and Ba/F3 (EGFR Del19/T790M/C797S) cell lines, with evident synergy. Conversely, little synergy was observed in NCI-H1975 (EGFR L858R/T790M/C797S) and PC9 (EGFR Del19/T790M/C797S) cell lines. (Zheng Q, et al., 2022)
A: Ba/F3 cells were likely chosen for their ability to grow in suspension and dependence on cytokine signaling, making them suitable for studying oncogenic kinase activity and drug resistance mechanisms associated with EML4-ALK/L1196M mutations.
A: Stability was likely confirmed through methods such as immunoblotting, functional assays measuring downstream signaling, or cell viability assays in the absence of growth factors, with continuous selection pressure applied.
A: Characterization may involve analysis of ALK phosphorylation, downstream signaling pathways, and functional implications in cell proliferation, survival, and response to ALK inhibitors such as crizotinib or lorlatinib.
A: Quality control likely included confirmation of EML4-ALK/L1196M expression levels, validation of its kinase activity and drug sensitivity, assessment of off-target effects, and validation of phenotypic changes associated with ALK modulation.
A: Comparative analysis with patient-derived samples or in vivo models helps validate the relevance of EML4-ALK/L1196M expression in oncogenic signaling, tumor progression, and response to ALK-targeted therapies, guiding the development of personalized treatment strategies for ALK-positive cancers.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Consistent reliability! The Human EGFR-DEL19/C797S Stable Cell Line in Ba/F3 cells ensures stable expression of EGFR variants, providing dependable results in cancer drug resistance studies.
Enabling advanced exploration! With stable EGFR-DEL19/C797S expression, I can investigate mechanisms of resistance to EGFR inhibitors with confidence, driving progress in targeted therapy research.
Remarkable performance! This cell line exceeds expectations, serving as a robust platform for studying EGFR-DEL19/C797S-targeted therapies and precision medicine approaches in lung cancer.
Streamlining research processes! Its stable expression simplifies experimental workflows, facilitating efficient data analysis and accelerating discoveries in drug resistance mechanisms.
An invaluable resource! The Human EGFR-DEL19/C797S Stable Cell Line has significantly enhanced my research capabilities, offering valuable insights into EGFR-driven oncogenesis and potential therapeutic interventions for drug-resistant tumors.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
